ArticleIranian journal of medical sciences2017
Efficacy of Risperidone Augmentation with Ondansetron in the Treatment of Negative and Depressive Symptoms in Schizophrenia: A Randomized Clinical Trial.
Article in Iranian journal of medical sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 4 syntheses or guidelines pooled it, 19 citations in OpenAlex.
- Serotonin type 3 receptor (5-HTNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Pooled it
- Major Adverse Cardiac Events with Ondansetron: A Systematic Review.Clinical pharmacology and therapeutics · 2026Pooled it
- Non-Clozapine interventions in treatment-resistant schizophrenia: a systematic review and meta-analysis.Molecular psychiatry · 2026Pooled it
- Selective 5HT3 antagonists and sensory processing: a systematic review.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022Pooled it
- Beneficial adjunctive effects of the 5HT3 receptor antagonist ondansetron on symptoms, function and cognition in early phase schizophrenia in a double-blind, 2 × 2 factorial design, randomised controlled comparison with simvastatin.Journal of psychopharmacology (Oxford, England) · 2024Trial
- Pharmacological Treatments of Negative Symptoms in Schizophrenia-An Update.Journal of clinical medicine · 2024Review
- Augmentation Therapies as Treatments for Coexisting Somatic Problems in Schizophrenia-A Systematic Review.Journal of clinical medicine · 2023Review
- Review
- Nanotechnology Approaches for Enhanced CNS Drug Delivery in the Management of Schizophrenia.Advanced pharmaceutical bulletin · 2022Review
- Current perspectives in treating negative symptoms of schizophrenia: A narrative review (Review).Experimental and therapeutic medicine · 2021Review
- Effect ofGalen medical journal · 2019Article
- Efficacy of different types of cognitive enhancers for patients with schizophrenia: a meta-analysis.NPJ schizophrenia · 2018Article
- New Targets for Schizophrenia Treatment beyond the Dopamine Hypothesis.International journal of molecular sciences · 2017Review
- The contribution of the cingulate cortex: treating depressive symptoms in first-episode drug naïve schizophrenia.International journal of clinical and health psychology : IJCHPArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGiven the potential role of the 5-hydroxytryptamine-3 receptor in the pathogenesis of schizophrenia, this study was performed to determine whether ondansetron plus risperidone could reduce the negative and depressive symptoms in patients with treatment-resistant schizophrenia.
methodsIn a double-blinded, placebo-controlled, randomized trial (IRCT registration # 201112125280N7), in 2012-2013 in Mashhad, Iran, 38 patients with treatment-resistant schizophrenia received risperidone either combined with a fixed dose (4-8 mg/d) of ondansetron (n=18) or with a placebo (n=20) for 12 weeks. The patients were evaluated using the Positive and Negative Syndrome Scale (PANSS), Wechsler's Adult Intelligence Scale-Revised (WAIS-R), and Hamilton's Rating Scale for Depression (HRSD) at baseline and 12 weeks later. Changes in the inventories were used to evaluate the efficacy of the treatment. The t test, Chi-square test, and SPSS (version 16) were used to analyze the data. The statistical significance was set atP<0.05.
resultsOndansetron plus risperidone was associated with a significantly larger improvement in the PANSS overall scale and subscales for negative symptoms and cognition than was risperidone plus placebo (P<0.001). The WAIS-R scale results indicated significant differences between the 2 groups before and after administrating the medicine and the placebo. The administration of ondansetron significantly improved visual memory based on the subtests of the WAIS (P<0.05). Ondansetron had no positive effects on depressive symptoms (effect size=0.13).
conclusionThis study confirmed that ondansetron, as an adjunct treatment, reduces negative symptoms in patients with schizophrenia and can be used as a potential adjunctive strategy particularly for negative symptoms and cognitive impairments.
Indexed as
Identifiers
28293046PMC5337760W2581007142What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.